CD19-directed CAR T-cell therapy with 4-1BB and CD3ζ co-stimulatory domains
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD19-directed CAR T-cell therapy with 4-1BB and CD3ζ co-stimulatory domains, covering 2026-02-09 to 2026-02-09. Get the full timeline:
Most recent: Clinical Trial Update: Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) [Phase 1, Phase 2]